An implant you can tune after it's inside the eye. Robert Chang has spent 30 years building toward exactly that.
There is a specific kind of engineer who is not content to build something that merely works. Robert Chang builds things that can be adjusted - after the fact, after the surgery, after the device is already inside the body. That instinct, trained at Cal Poly and MIT, has run as a through-line across every company he has built or led.
The Calibreye Titratable Glaucoma Therapy (TGT) Surgical System is not a conventional aqueous shunt. Most glaucoma implants are fixed-flow: once they are in, they are in. Calibreye has four discrete settings, adjustable non-invasively at a slit lamp in a clinic. No second surgery. A physician can tune the outflow weeks after the initial procedure, or months later as a patient's pressure profile evolves. That is the product - and Robert Chang has been President and CEO of Myra Vision since 2019, steering it from a $3 million seed round to its first US patient enrolled in the ADAPT pivotal study in January 2026.
He joined Myra Medical (as it was then called) from MVRx, a company he co-founded and ran as CEO before its acquisition in May 2021. Before that: Sadra Medical, EVP and CTO, acquired by Boston Scientific. Before that: co-founder of Ample Medical. Earlier still: President and COO of IsoStent at 34. The pattern is a serial founder who keeps finding the harder version of the same problem - complex cardiovascular and ocular devices that require both engineering precision and clinical sensibility.
What makes Chang unusual in medtech is the breadth. He holds an SM in Mechanical Engineering from MIT and started his career as an associate product manager at Devices for Vascular Intervention in 1991 - when the field was still sorting out how stents even worked. That technical grounding, combined with the executive repetitions across multiple startups, produces the kind of leader who can argue materials science with a CTO and negotiate a Series B term sheet the same afternoon.
From the stent labs of Silicon Valley in 1991 to the glaucoma surgery suites of 2026. Every stop built on the last.
Glaucoma is a slow catastrophe. It affects an estimated 66 million people worldwide, but its damage - progressive, irreversible loss of peripheral vision - is invisible to patients until it is too late. The standard surgical intervention, the aqueous shunt, drains fluid from the eye to reduce intraocular pressure. Most existing shunts do this passively: a fixed channel, a fixed flow. If the pressure isn't right a month after surgery, there are few good options.
Chang's bet at Myra Vision is that adjustability changes the clinical math entirely. The Calibreye system implants once, then lets a glaucoma specialist dial the outflow up or down in-office, at the slit lamp, with no additional procedure. Four settings. Non-invasive. The kind of personalized therapy that is self-evident once described, but requires years of engineering to achieve in a 0.30mm-thick implant made of silicone and nitinol.
The Shifamed connection is not incidental. Chang was EVP and CTO at Sadra Medical, a Shifamed legacy company that Boston Scientific acquired - so when Shifamed founder Amr Salahieh looked for a CEO to run the newly seeded Myra Medical in 2019, Chang was a known quantity. Salahieh described him as the ideal leader: "Their combined decades of experience make them an ideal team to drive Myra forward."
From seed to Series B in four years, first-in-human in 2023, FDA IDE approval in August 2025, first ADAPT patient enrolled in January 2026: the cadence of Myra Vision's clinical progress maps almost exactly to Chang's track record of deliberate, milestone-by-milestone execution.
Led Myra Vision through $50M+ total fundraising (seed to Series B)
Achieved first-in-human use of Calibreye System - September 2023
Secured FDA conditional IDE approval for ADAPT study - August 2025
Enrolled first US patient in ADAPT pivotal clinical study - January 2026
Successfully exited MVRx via private acquisition - May 2021
Led Sadra Medical as EVP/CTO to Boston Scientific acquisition
"We are pleased to close this round of financing with strong continued support from our investors. The team has made tremendous progress and we look forward to the next step towards delivering this meaningful solution for glaucoma patients."
Series B Close - June 2023"This first-in-human experience marks an important milestone as Myra transitions to a clinical stage company."
First-In-Human Study Launch - September 2023"This FDA approval to initiate our ADAPT study marks a significant milestone for our company as we advance our mission to deliver innovation to glaucoma care."
FDA IDE Approval - August 2025Robert Chang discusses Myra Vision's technology and mission.